JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3–Survivin Axis

Daeun Kim, Young-Ha Kim, Gaeun Choi, Chunhoo Cheon, Seong-Gyu Ko, Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Republic of Korea, Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Republic of Korea, Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Republic of Korea

Integrative Cancer Therapies

Published online on August 04, 2026

Abstract

Integrative Cancer Therapies, Volume 25, January-December 2026.
IntroductionFirst-generation EGFR-TKIs in NSCLC frequently lose efficacy as a result of the secondary EGFR-T790M mutation and a “persistent-STAT3” prosurvival pathway that sustains STAT3–survivin signaling in the face of EGFR inhibition. Preclinical ...